Arrowhead has enrolled 70 patients in a rare cholesterol trial, but can zodasiran clear the Phase 3 bar?
Arrowhead completes Phase 3 YOSEMITE enrollment as zodasiran faces a crucial test of LDL cholesterol lowering in patients with severe HoFH.
Pharma & Biotech
Pharma & Biotech
SHASTA-3 and SHASTA-4 results support Arrowhead Pharmaceuticals’ planned plozasiran FDA filing
Arrowhead’s Phase 3 SHASTA data show deep triglyceride reductions and fewer pancreatitis events, supporting a planned 2026 U.S. filing.
Pharma & Biotech
Is Arrowhead’s plozasiran becoming the RNAi drug to watch in extreme triglyceride disorders?
Arrowhead’s plozasiran data ease dosing concerns in complex patients, but Phase 3 results will decide its broader triglyceride market role.
Pharma & Biotech
What Madrigal Pharmaceuticals, Inc.’s siRNA deal signals for the future of MASH treatment
Can Madrigal Pharmaceuticals, Inc. reshape MASH treatment with ARO-PNPLA3? Discover what this precision strategy means for the future.
Pharma & Biotech
Arrowhead just unlocked Australia for REDEMPLO, but the bigger RNAi test starts now
Arrowhead has regulatory momentum in rare lipid disease. The harder test is turning REDEMPLO approval into durable global uptake.
Pharma & Biotech
Arrowhead’s plozasiran clears CHMP: what a positive opinion for FCS means for siRNA’s regulatory arc in Europe
Plozasiran clears CHMP but the real test is reimbursement. Europe's HTA bodies will now decide whether clinical FCS diagnosis is enough.
Pharma & Biotech
Can Arrowhead Pharmaceuticals expand plozasiran without the Ionis patent fight becoming a commercial overhang?
Arrowhead Pharmaceuticals is advancing plozasiran fast, but can it overcome the Ionis patent dispute? Read the deeper legal and commercial analysis.
Pharma & Biotech
Arrowhead Pharmaceuticals strengthens plozasiran’s severe hypertriglyceridemia case with durable ACC.26 data
Arrowhead Pharmaceuticals’ plozasiran posted durable triglyceride reductions at ACC.26. Read what the long-term data could change next.